Skip to content

Role of Asthisharinkhala Ghana Guggulu in the management of Osteoarthritis

A CLINICAL STUDY TO EVALUATE THE EFFICACY OF ASTHISHARINKHALA GHANA IN THE MANAGEMENT OF OSTEOARTHARIRIS

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/05/014093
Enrollment
10
Registered
2018-05-24
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M179- Osteoarthritis of knee, unspecified Health Condition 2: null- patient with osteoarthritis

Interventions

Intervention1: asthisharinkhala ghana guggulu: Asthishrankhala Ghana Guggulu 2 tab B.D (1 gram), with the Anupana of Ushna Jala for 30 days Control Intervention1: not applicable: not applicable

Sponsors

OPD and IPD department of panchakarma
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a. Having sign and symptoms of Sandhivata (Osteoarthritis) as given below: 1. Sandhi Shula (pain in the joint) 2. Sandhi Shotha (Swelling in the joints) 3. Sandhigraha (Morning Stiffness) 4. Akunchana Prasaranayoh Vedana (Pain during Flexion and extension) 5. Sparsha Asahyata (Tenderness) 6. Sandhisphutana (Cracking of the joints) 7. Crepitus in the joint. b. Diagnostic Findings: 1. Radiologic Osteophytes (If present) c. Chronicity less than or equal to 5 years

Exclusion criteria

Exclusion criteria: 1. Patients below 30 and above 70 years of age. 2. Cases which require surgical intervention will be excluded. 3. Patient, suffering from any chronic debilitating disease like T.B., D.M., Rheumatoid Arthritis, Gout, Varicose veins, Asthma & other chronic problems etc. and having other serious pathology. 4. Pregnant lady and lactating mother

Design outcomes

Primary

MeasureTime frame
To assess the effect of therapy all sign and symptoms were given scoring depending upon there severity. 1. Complete relief : 100% 2. Marked improvement : 76% to 99 3. Moderate improvement : 51% to 75 % 4. Mild improvement : 26 % to 50 % 5. No improvement : 0% to 25 %Timepoint: 2 year

Secondary

MeasureTime frame
Exacerbation in signs and synptomsTimepoint: 30 DAYS

Countries

India

Contacts

Public ContactAlok Kumar Srivastava

Rishikul campus haridwar

virgo.alok@gmail.com9045087121

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026